Mewes T, Dutz S, Ravens U, Jakobs K H
Institut für Pharmakologie, Universität GH Essen, Germany.
Circulation. 1993 Dec;88(6):2916-22. doi: 10.1161/01.cir.88.6.2916.
The cardiac calcium channel is known to be modulated by catecholamines via beta-adrenoceptors acting through intermediary GTP-binding regulatory proteins (G proteins). In biochemical studies on isolated membranes and reconstituted systems, it has been demonstrated that various G protein-coupled receptors, including beta-adrenoceptors, can activate G proteins and also intracellular second messengers like cyclic AMP (cAMP) even in the absence of an agonist and that antagonists can block this empty receptor action. We examined electrophysiologically whether agonist-free beta-adrenoceptors can modulate L-type calcium currents (ICa) in intact cardiac myocytes.
Cardiomyocytes were isolated from ventricles of guinea pig and human hearts and from human right atrial appendage. The patch-clamp technique was applied in the single electrode mode to measure whole-cell ICa. Modulation of calcium currents by beta-adrenoceptor antagonists, without addition of an agonist, was studied in the absence and presence of the direct adenylyl cyclase activator forskolin and the cAMP analog adenosine cyclic 3',5'-monophosphorothioate (Sp-cAMPS). In the presence of forskolin (0.5 mumol/L), an agent known to sensitize the adenylyl cyclase signal transduction system for receptor regulation, addition of the beta 1-selective antagonist atenolol and the nonselective antagonist propranolol (but not of the beta 2-selective antagonist ICI 118,551) caused a marked reduction of ICa in a concentration-dependent and stereoselective manner. The inhibitory effect of atenolol was reversible after washing out and was found to be half maximal and maximal (50% reduction) at about 50 and 300 nmol/L, respectively. In the absence of forskolin, inhibition of ICa by atenolol was markedly less (18% at 10 mumol/L atenolol). Finally, in contrast to forskolin-stimulated currents, atenolol (1 mumol/L) did not reduce calcium currents activated by the protein kinase A activator Sp-cAMPS (0.1 mmol/L), causing by itself a similar increase in calcium currents as forskolin.
In isolated guinea pig and human cardiomyocytes, agonist-free beta-adrenoceptors are functionally active and can stimulate L-type calcium currents, an effect blocked by receptor-specific antagonists.
已知心脏钙通道可通过β-肾上腺素能受体经中间的鸟苷三磷酸结合调节蛋白(G蛋白)介导受儿茶酚胺调控。在对分离膜和重组系统的生化研究中,已证实包括β-肾上腺素能受体在内的各种G蛋白偶联受体即使在无激动剂的情况下也能激活G蛋白以及细胞内第二信使如环磷酸腺苷(cAMP),并且拮抗剂可阻断这种空受体作用。我们用电生理学方法研究了无激动剂的β-肾上腺素能受体是否能调节完整心肌细胞中的L型钙电流(ICa)。
从豚鼠和人的心室以及人的右心耳分离出心肌细胞。采用单电极模式的膜片钳技术测量全细胞ICa。在不存在和存在直接腺苷酸环化酶激活剂福斯可林以及cAMP类似物3',5'-环磷硫腺苷(Sp-cAMPS)的情况下,研究了不添加激动剂时β-肾上腺素能受体拮抗剂对钙电流的调节作用。在存在福斯可林(0.5μmol/L)(一种已知可使腺苷酸环化酶信号转导系统对受体调节敏感的试剂)的情况下,添加β1选择性拮抗剂阿替洛尔和非选择性拮抗剂普萘洛尔(但不包括β2选择性拮抗剂ICI 118,551)会导致ICa以浓度依赖性和立体选择性方式显著降低。阿替洛尔的抑制作用在洗脱后是可逆的,并且在约50和300 nmol/L时分别发现其半数最大抑制浓度和最大抑制浓度(降低50%)。在不存在福斯可林的情况下,阿替洛尔对ICa的抑制作用明显较小(10μmol/L阿替洛尔时为18%)。最后,与福斯可林刺激的电流相反,阿替洛尔(1μmol/L)不会降低蛋白激酶A激活剂Sp-cAMPS(0.1 mmol/L)激活的钙电流,其本身引起的钙电流增加与福斯可林相似。
在分离的豚鼠和人心肌细胞中,无激动剂的β-肾上腺素能受体具有功能活性,可刺激L型钙电流,该效应可被受体特异性拮抗剂阻断。